Subtopic Deep Dive
CALR Mutations in Essential Thrombocythemia
Research Guide
What is CALR Mutations in Essential Thrombocythemia?
CALR mutations are somatic frameshift mutations in the calreticulin gene, primarily type 1 (52-bp deletion) and type 2 (5-bp insertion), driving essential thrombocythemia in JAK2-negative myeloproliferative neoplasms.
These mutations occur in 20-25% of essential thrombocythemia cases lacking JAK2 V617F or MPL alterations (Klampfl et al., 2013, 1929 citations). They activate the thrombopoietin receptor pathway via novel C-terminal sequences. WHO classifications recognize them as diagnostic markers (Arber et al., 2016, 9991 citations).
Why It Matters
CALR mutations enable precise diagnosis of JAK2-negative essential thrombocythemia, guiding risk stratification and treatment. Patients with CALR mutations show superior survival compared to triple-negative cases (Tefferi et al., 2014, 709 citations). They inform prognostication, with type 1 mutations linked to higher thrombosis risk and type 2 to younger onset (Rumi et al., 2014, 378 citations). Genomic profiling incorporating CALR improves clinical trial eligibility and personalized therapy in myeloproliferative neoplasms.
Key Research Challenges
Distinguishing Mutation Types
Type 1 and type 2 CALR mutations differ in megakaryocyte morphology and clinical outcomes, complicating uniform treatment. Accurate subtyping requires sequencing beyond PCR (Klampfl et al., 2013). Prognosis varies, with type 1 showing myelofibrosis progression risk (Tefferi et al., 2014).
Prognostic Heterogeneity
CALR-mutated ET patients have indolent courses but variable blast transformation risks compared to JAK2-mutated cases. Long-term survival data reveal inferior outcomes to matched populations (Tefferi et al., 2014, 709 citations). Additional mutations influence clonal evolution (Grinfeld et al., 2018).
Therapeutic Targeting
No direct CALR inhibitors exist; reliance on JAK inhibitors shows variable efficacy by driver mutation. Mutant CALR activates MPL independently of JAK2 (Vainchenker and Královics, 2016). Clinical trials need mutation-specific endpoints (Barbui et al., 2018).
Essential Papers
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian et al. · 2016 · Blood · 10.0K citations
Abstract The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues was last updated in 2008. Since then, there have been numerous advances in the identi...
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl, Heinz Gisslinger, Ashot S. Harutyunyan et al. · 2013 · New England Journal of Medicine · 1.9K citations
Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients...
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson et al. · 2014 · Blood · 709 citations
Key Points Survival in ET is superior to that of PV, regardless of mutational status, but remains inferior to the sex- and age-matched US population. JAK2/CALR/MPL mutational status is prognostical...
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker, Róbert Královics · 2016 · Blood · 634 citations
Abstract The genetic landscape of classical myeloproliferative neoplasm (MPN) is in large part elucidated. The MPN-restricted driver mutations, including those in JAK2, calreticulin (CALR), and mye...
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Sally Thomas, John A. Snowden, Martin P. Zeidler et al. · 2015 · British Journal of Cancer · 626 citations
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger et al. · 2018 · Blood Cancer Journal · 611 citations
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
Jacob Grinfeld, Jyoti Nangalia, E. Joanna Baxter et al. · 2018 · New England Journal of Medicine · 581 citations
BACKGROUND: Myeloproliferative neoplasms, such as polycythemia vera, essential thrombocythemia, and myelofibrosis, are chronic hematologic cancers with varied progression rates. The genomic charact...
Reading Guide
Foundational Papers
Start with Klampfl et al. (2013) for mutation discovery in JAK2-negative ET/PMF; follow Tefferi et al. (2014) for survival/prognosis data across drivers.
Recent Advances
Grinfeld et al. (2018) for genomic classification; Barbui et al. (2018) for updated WHO diagnostic criteria and management.
Core Methods
Exon 9 Sanger sequencing or NGS for detection; mutant CALR protein modeling for megakaryocyte effects; Kaplan-Meier for prognosis (Tefferi et al., 2014).
How PapersFlow Helps You Research CALR Mutations in Essential Thrombocythemia
Discover & Search
Research Agent uses searchPapers and citationGraph to map CALR literature from Klampfl et al. (2013) central node, revealing 1929 citing papers on ET prognosis. exaSearch queries 'CALR type 1 vs type 2 essential thrombocythemia survival' for latest genomic studies; findSimilarPapers expands to Tefferi et al. (2014) cluster.
Analyze & Verify
Analysis Agent applies readPaperContent to extract mutation frequencies from Klampfl et al. (2013), then verifyResponse with CoVe checks claims against Arber et al. (2016) WHO criteria. runPythonAnalysis processes survival data from Tefferi et al. (2014) via pandas for Kaplan-Meier curves; GRADE grading scores evidence as high for diagnostic utility.
Synthesize & Write
Synthesis Agent detects gaps in CALR-specific therapies via contradiction flagging between Vainchenker (2016) pathway data and trial outcomes. Writing Agent uses latexEditText for mutation diagrams, latexSyncCitations for 50+ MPN papers, and latexCompile for publication-ready reviews; exportMermaid visualizes JAK2/CALR/MPL driver hierarchies.
Use Cases
"Compare survival curves for CALR vs JAK2 ET patients from Tefferi 2014"
Research Agent → searchPapers('Tefferi 2014 ET survival') → Analysis Agent → readPaperContent + runPythonAnalysis(pandas/matplotlib for Kaplan-Meier) → statistical p-values and GRADE-verified plot output.
"Draft LaTeX review on CALR mutations diagnostic criteria"
Synthesis Agent → gap detection on WHO papers → Writing Agent → latexEditText('insert CALR frameshift section') → latexSyncCitations(Arber 2016, Klampfl 2013) → latexCompile → PDF with figures.
"Find code for CALR mutation simulator in MPN models"
Research Agent → paperExtractUrls(Grinfeld 2018) → paperFindGithubRepo → Code Discovery → githubRepoInspect → validated Python scripts for clonal evolution simulation.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ CALR-ET papers: searchPapers → citationGraph → DeepScan (7-step: extract → verify → GRADE → synthesize). Theorizer generates hypotheses on type 1/type 2 megakaryocyte effects from Klampfl (2013) + Vainchenker (2016). DeepScan verifies mutation order impacts via CoVe on Ortmann et al. (2015).
Frequently Asked Questions
What defines CALR mutations in essential thrombocythemia?
Somatic frameshift mutations in CALR exon 9, type 1 (52-bp deletion, L367fs*46) and type 2 (5-bp insertion, K385fs*47), occur in 20-25% JAK2-negative ET cases (Klampfl et al., 2013).
What detection methods identify CALR mutations?
PCR followed by Sanger sequencing or NGS panels targeting exon 9; WHO criteria mandate testing in JAK2/MPL-negative ET (Arber et al., 2016).
What are key papers on CALR in ET?
Klampfl et al. (2013, NEJM, 1929 citations) discovered mutations; Tefferi et al. (2014, Blood, 709 citations) showed superior ET survival.
What open problems exist in CALR-mutated ET?
Optimal therapies targeting mutant CALR-MPL interaction; predicting progression to myelofibrosis by type/subclones (Vainchenker and Královics, 2016).
Research Myeloproliferative Neoplasms: Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching CALR Mutations in Essential Thrombocythemia with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers